Overview

Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) Following a Single Oral Dose in Healthy Male Subjects

Status:
Completed

Trial end date:
2020-10-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the absorption, metabolism, and excretion of [14C]-TBPM-PI-HBr and to characterize and determine the metabolites present in plasma, urine, and where possible, feces in healthy male subjects following a single oral administration.

Phase:

Phase 1

Details

Lead Sponsor:

Spero Therapeutics

Collaborator:

Covance